🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 10 of 116

  1. Gazyvaro 1,000 mg concentrate for solution for infusion., Chlorambucil 2 mg tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclexta, Venclyxto, Venclexta, Venclyxto, Venclexta, Venclyxto

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  2. Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules

    AstraZeneca AB

    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  3. Gefitinib

    AstraZeneca

    Non-Small-Cell Lung Carcinoma

    phase 3 small molecule completed

    1 trial

  4. Gefitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. Gemcitabine

    AstraZeneca

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  6. Gemcitabine 38 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Gilead Sciences Pty Limited

    PD-L1 Positive Metastatic Triple-Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  7. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Revlimid 25 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Oxaliplatin 5mg/ml Concentrate for Solution for Infusion, Revlimid 5 mg hard capsules, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Truxima 500 mg concentrate for solution for infusion, Revlimid 20 mg hard capsules, Truxima 100 mg concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  8. Gemcitabine Eugia 40 mg/ml solution à diluer pour perfusion, RILVEGOSTOMIG, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Hihg risk of cholangiocarcinoma intra hépatic resectable

    phase 3 small molecule active

    1 trial

  9. Gemcitabine,Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  10. General anesthesia and opioids

    Elan Pharma International

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  11. Gilteritinib

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  12. HD201

    Prestige Biopharma Belgium

    HER2 Positive Breast Cancer

    phase 3 small molecule completed

    1 trial

  13. HIPEC with neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  14. HLX02

    Shanghai Henlius Biotech

    Breast Cancer

    phase 3 mab completed

    1 trial

  15. HOLOXAN 2000 mg, poudre pour usage parentéral, DETICENE 100 mg, poudre et solvant pour solution pour perfusion, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Resectable, non-metastatic soft-tissue sarcoma (STS)

    phase 3 small molecule active

    1 trial

  16. HVA

    The First People's Hospital of Lianyungang

    Newly Diagnosed Acute Myeloid Leukemia With High Risk

    phase 3 small molecule active

    1 trial

  17. HYCAMTIN 4 mg powder for concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  18. HYDROCORTISONE, PREDNISONE ACETATE, ENZALUTAMIDE, DEXAMETHASONE ACETATE, PREDNISONE, Opevesostat, ABIRATERONE ACETATE, DEXAMETHASONE, HYDROCORTISONE , HYDROCORTISONE, FLUDROCORTISONE, ABIRATERONE ACETATE, PREDNISOLONE, HYDROCORTISONE, FLUDROCORTISONE ACETATE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  19. Herceptin

    Hoffmann-La Roche

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  20. Herceptin 150 mg powder for concentrate for solution for infusion, DS-8201a, Perjeta 420 mg concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    Early stage HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

  21. Herceptin 150 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Solid Malignant Tumors

    phase 3 small molecule active

    1 trial

  22. Herzuma 150 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DS-8201a, CAPECITABINE, 5-Fluorouracil Ebewe 50 mg/ml concentrat pentru soluţie injectabilă/perfuzabilă, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CAPECITABINE, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi Sankyo

    Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer

    phase 3 small molecule active

    1 trial

  23. Herzuma 420 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, Perjeta 420 mg concentrate for solution for infusion, CYCLOPHOSPHAMIDE, DS-8201a, PACLITAXEL, DOXORUBICIN, Herzuma 150 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE

    AstraZeneca AB

    Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)

    phase 3 small molecule active

    1 trial

  24. Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 3 other active

    1 trial

  25. IAC regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  26. IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, IBRANCE 75 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules

    Partner Therapeutics Limited

    Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.

    phase 3 small molecule active

    1 trial

  27. IBRANCE 125 mg film-coated tablets, Placebo Giredestrant, IBRANCE 100 mg hard capsules, RO7197597, Placebo Letrozole, IBRANCE 75 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, Femara® 2,5 mg Filmtabletten, IBRANCE 100 mg film-coated tablets

    Hoffmann-La Roche

    ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

    phase 3 small molecule active

    1 trial

  28. IBRANCE 75 mg film-coated tablets, GOSERELIN ACETATE, Placebo to match camizestrant, Placebo to match anastrozole, camizestrant, ABEMACICLIB, Placebo to match letrozole, IBRANCE 100 mg film-coated tablets, Arimidex® 1 mg Filmtabletten, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, LETROZOLE, LEUPRORELIN ACETATE, ABEMACICLIB, Camizestrant, ABEMACICLIB

    AstraZeneca AB

    Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  29. IBRUTINIB, PIRTOBRUTINIB, PIRTOBRUTINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  30. ICM ADX-2191 injection

    Aldeyra Therapeutics

    Primary Vitreoretinal Lymphoma

    phase 3 small molecule active

    1 trial

  31. IDE196

    IDEAYA Biosciences

    Metastatic Uveal Melanoma

    phase 3 small molecule active

    2 trials

  32. IDE196 (LXS196), IDE196 (LXS196)

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    1 trial

  33. IFx-Hu2.0

    TuHURA Biosciences, Inc./NV

    Advanced Or Metastatic Merkel Cell Carcinoma

    phase 3 small molecule active

    2 trials

  34. IM JZP-458

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  35. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Wuhan Createrna Science and Technology Co., Ltd

    Small-cell lung cancer, extensive stage

    phase 3 small molecule active

    1 trial

  36. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  37. IMFINZI 50 mg/mL concentrate for solution for infusion., DURVALUMAB, MYCOPHENOLATE MOFETIL, Placebo, OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., INFLIXIMAB

    AstraZeneca AB

    Non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  38. IMFINZI 50 mg/mL concentrate for solution for infusion., Futibatinib, Zercepac 150 mg powder for concentrate for solution for infusion., Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets, JZP598, Zejula 100 mg hard capsules, Nerlynx 40 mg film-coated tablets, IVOSIDENIB, CISPLATIN, PEMBROLIZUMAB, GEMCITABINE

    Ningbo Cancer Hospital

    Advanced Biliary Cancer (ABC)

    phase 3 small molecule active

    1 trial

  39. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., OXALIPLATIN, GEMCITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with hepatocellular carcinoma with high tumor burden.

    phase 3 small molecule active

    1 trial

  40. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., Mycophenolate Mofetil 500 mg film-coated tablets, Nexavar 200 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Advanced hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  41. IMFINZI 50 mg/mL concentrate for solution for infusion., Tiragolumab, IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non−small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  42. IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, LENVIMA 4 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Locoregional Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  43. IMJUDO 20 mg/ml concentrate for solution for infusion., PACLITAXEL SANDOZ 6 mg/ml, solution à diluer pour perfusion, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CARBOPLATINE KABI 10 mg/ml, solution à diluer pour perfusion, IMFINZI 50 mg/mL concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatine Accord 1 mg/ml concentraat voor op

    The George Institute

    Synchronous oligometastatic non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  44. INAVOLISIB, PALBOCICLIB, Faslodex 250 mg solution for injection., INAVOLISIB, PALBOCICLIB, INAVOLISIB, PALBOCICLIB, INAVOLISIB

    Hoffmann-La Roche

    HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  45. INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  46. INCA33890, Placebo contains the same formulation buffer, 10 mM acetate, 9% (w/v) sucrose and 0.02% (w/v) polysorbate 80, at pH 5.5, without the active pharmaceutical ingredient., CALCIUM FOLINATE, BEVACIZUMAB, OXALIPLATIN, FLUOROURACIL

    Incyte

    Metastatic Microsatellite Stable Colorectal Cancer

    phase 3 small molecule active

    1 trial

  47. INFLIXIMAB , MYCOPHENOLIC ACID , SALINE, ETOPOSIDE , CARBOPLATIN , PEMETREXED , IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN , PACLITAXEL

    AstraZeneca AB

    Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)

    phase 3 small molecule active

    1 trial

  48. INFLIXIMAB, DS-8201a, AZD6738, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients with non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.